3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
5
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Recurrence
2
Breast Neoplasms
2
Stage IIIb and IV Non Small Cell Lung Cancer
1
Solid Tumor, Adult
1
Rare Diseases
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplastic Syndromes, Hereditary
1
Neoplasm, Residual
1
Multiple Myeloma
1
Mouth Neoplasms
1
Microsatellite Instability
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Genetic Predisposition to Disease
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
COVID-19
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
53
Etoposide
33
Temozolomide
28
Irinotecan
28
Melphalan
25
Filgrastim
25
Topotecan
24
Carboplatin
24
3-Iodobenzylguanidine
23
Isotretinoin
20
Granulocyte Colony-Stimulating Factor
17
sargramostim
16
humanized 3F8 anti-GD2 monoclonal antibody
16
dinutuximab
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
fludarabine
15
Vincristine
15
Doxorubicin
15
Cisplatin
15
Peripheral Blood Stem Cell Transplantation
14
Interleukin-2
14
Busulfan
13
naxitamab
12
Thiotepa
12
Radiotherapy
12
aldesleukin
11
fludarabine phosphate
10
etoposide phosphate
8
Mesna
8
Ifosfamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroblastoma
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled